



# The global prevalence of *Toxocara* spp. in pediatrics: a systematic review and meta-analysis

Behnam Abedi, MSc<sup>1</sup>, Mehran Akbari, MSc<sup>2</sup>, Sahar KhodaShenas, MSc<sup>3</sup>, Alireza Tabibzadeh, MSc<sup>4</sup>, Ali Abedi, MSc<sup>5</sup>, Reza Ghasemikhah, PhD<sup>6</sup>, Marzieh Soheili, MD<sup>7,8</sup>, Shnoo Bayazidi, MSc<sup>9</sup>, Yousef Moradi, PhD<sup>10</sup>

<sup>1</sup>Department of Medical Laboratory, Khomein University of Medical Sciences, Khomein, Iran; <sup>2</sup>Department of Nursing, Khomein University of Medical Sciences, Khomein, Iran; <sup>3</sup>Department of Parasitology and Mycology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran; <sup>4</sup>Departments of Virology, Iran University of Medical Sciences, Tehran, Iran; <sup>5</sup>Department of Microbiology, Islamic Azad University of Arak, Arak, Iran; <sup>6</sup>Department of Parasitology and Mycology, School of Medicine, Arak University of Medical Sciences, Arak, Iran; <sup>7</sup>Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran; <sup>8</sup>Human Revivification Society of Congress 60, Tehran, Iran; <sup>9</sup>Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran; <sup>10</sup>Social Determinants of Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran

**Background:** Toxocariasis is a zoonotic parasitic disease caused by *Toxocara canis* and *Toxocara cati* in humans. Various types of *T. canis* are important.

**Purpose:** The current study aimed to investigate the prevalence of *Toxocara* spp. in pediatrics in the context of a systematic review and meta-analysis.

**Methods:** The MEDLINE (PubMed), Web of Sciences, Embase, Google Scholar, Scopus, and Cumulative Index of Nursing and Allied Health databases were searched to identify peer-reviewed studies published between January 2000 and December 2019 that report the prevalence of *Toxocara* spp. in pediatrics. The evaluation of articles based on the inclusion and exclusion criteria was performed by 2 researchers individually.

**Results:** The results of 31 relevant studies indicated that the prevalence of *Toxocara* spp. was 3%–79% in 10,676 cases. The pooled estimate of global prevalence of *Toxocara* spp. in pediatrics was 30 (95% confidence interval, 22%–37%;  $I^2=99.11\%$ ;  $P=0.00$ ). The prevalence was higher in Asian populations than in European, American, and African populations.

**Conclusion:** Health policymakers should be more attentive to future research and approaches to *Toxocara* spp. and other zoonotic diseases to improve culture and identify socioeconomically important factors.

**Key words:** Learning disability, Neurobiology, Reading disability (dyslexia)

## Key message

Is the global prevalence of toxocariasis high among children? The prevalence of toxocariasis is high in pediatric patients. Asian children are more susceptible to the disease than other children. Its virulence varies among different socioeconomic classes in

various countries. Hand washing after soil contact, routine pet deworming, and appropriate disposal of pet feces in households with Asian pediatrics are needed to prevent toxocariasis.

## Introduction

Toxocariasis or visceral migraine laryngeal syndrome is a zoonotic parasitic disease caused by *Toxocara canis* and *Toxocara cati* in humans. Various types of *T. canis* in particular can be important.<sup>1,2</sup> Each adult worm in the intestines of infected dogs and cats can release a large number of eggs daily through defecation. Toxocariasis is mostly transmitted to humans via water, food, and soil contaminated with eggs.<sup>2,3</sup> The eggs of this parasite are opened after entering the human digestive system. The larvae then pass through the intestinal mucosa to the bloodstream and diffuse into organs such as the liver, brain, and eye. Although the larva will be recognized and limited by the immune system forming granuloma, they can survive and persist in this form for up to 11 years.<sup>4</sup>

The visceral larva migrans (VLM), ocular larvae (OLM), and overt toxocariasis are the most common types of larvae. The clinical symptoms of infection are nonspecific but can include neurological, ocular, pulmonary (asthmatic), dermatological, and rheumatoid arthritis.<sup>5</sup> The pathology of this parasite is variable, but it can induce peripheral eosinophilia (20%–40%) and fever of unknown origin. The prevalence of parasites varies among geographic regions at rates of 2%–90%.<sup>6–8</sup>

Pediatrics are more susceptible to *Toxocara* infection since they are more likely to place a contaminated hand or even an egg into their mouth.<sup>9</sup> Seroepidemiological evaluations in different countries indicated a global distribution of toxocariasis. Considering the importance of the prevalence of this parasite in the population, this study aimed to evaluate the prevalence of

Corresponding author: Yousef Moradi, PhD, Social Determinants of Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran

✉ Email: [yousefmoradi211@yahoo.com](mailto:yousefmoradi211@yahoo.com), <https://orcid.org/0000-0002-2936-5930>

Received: 12 June, 2020, Revised: 22 January, 2021, Accepted: 22 January, 2021

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2021 by The Korean Pediatric Society

toxocariasis in pediatric patients younger than 20 years of age based on a systematic review and meta-analysis of published studies.

## Methods

This study was performed according to the MOOSE (Meta-Analyses of Observational Studies in Epidemiology) and the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses).<sup>10-12)</sup>

### 1. Search strategy

In this systematic review, we assessed all original research studies that were relevant to the topic by searching the MEDLINE (PubMed), Web of Sciences, Embase, Google Scholar, Scopus, and Cumulative Index of Nursing and Allied Health databases using keywords such as toxocariasis, *Toxocara*, *Toxocara*-antibodies, Pediatrics, *Toxocara canis*, and *Toxocara cati*. The search was limited to articles published between January 2000 and December 2019. The researchers searched these databases and manually searched the reference lists and gray literature. Duplicate entries were reviewed by considering the title of published papers, authors, year of publication, and specifications of the source types. In questionable records, the texts were compared. After abstract and title review, some of the articles were eliminated. The retrieved papers were evaluated by 2 researchers (YM, BA) based on the inclusion and exclusion criteria.

### 2. Eligibility criteria

For the current study, the inclusion criteria were publication in the English language and publication between January 2000 and December 2019. The study design and methodologies were cross-sectional. All other studies, such as reviews or meta-analyses, were excluded from the screening. Articles that were

conducted on animals were also excluded.

We included all English observational studies published between January 2000 to December 2019 that assessed the prevalence of toxocariasis, therapeutic management, signs, and symptoms in pediatric patients with toxocariasis. Cross-sectional studies were also included. We excluded duplicate non-peer-reviewed, review, or meta-analysis articles and papers for which the abstracts and full texts were not available.

### 3. Data extraction

All of the included studies were listed by EndNote software (EndNote X7, Thomson Reuters, Toronto, ON, Canada) and subjected to review and data extraction by 3 independent authors. Two reviewers independently (BA and RGH) extracted the required data from the data contained in the identified articles using a uniform Excel sheet. Discrepancies in the extracted data were resolved through consensus. If agreement could not be reached, it was resolved by referral to a third investigator (YM). For the current study, the data extraction section contained the first author's name, year of publication, study location, study type, sample size, age, positive population prevalence, and method of detecting the infection.

### 4. Risk of bias

The quality of all studies was assessed by 2 independent authors using the Modified Newcastle-Ottawa Scale for cross-sectional studies.<sup>13)</sup>

### 5. Statistical analysis

We used a random-effects model to generate a pooled prevalence presented as percentage and 95% confidence interval (CI) with Metaprop order. Interstudy heterogeneity was assessed using the  $I^2$  heterogeneity statistic reported as a percentage (%) to determine the extent of interstudy variation. A forest plot was used to present the meta-analysis results schematically. Egger test and a funnel plot were applied to evaluate the presence of




Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram and search strategy results.

publication bias. In addition, a subgroup analysis was performed to identify different sources of heterogeneity. The statistical analysis was performed using STATA 15.0 (Stata Corp., College Station, TX, USA), and statistical significance was set at  $P < 0.05$ .

## Results

The conducted search retrieved 2,395 studies. After duplicate removal and title and abstract screening, 276 relevant studies remained. The search and screening results are illustrated in Fig. 1. The assessment of 31 studies revealed that the prevalence of *Toxocara* was 3%–79% in 10,676 cases. Of the total number of children (10,676), 3,525 had *Toxocara* infection (Table 1). In addition, most of the conducted studies used enzyme-linked immunosorbent assay (ELISA) to diagnose the infection. Furthermore, in most of the mentioned studies, the patients were younger than 12 years of age. The results from the different included studies are listed in Table 1.

The results demonstrated that the pooled prevalence of

*Toxocara* in pediatric patients worldwide was 30 (95% CI, 22%–37%;  $I^2=99.11\%$ ;  $P=0.00$ ) (Fig. 2), but since the CI of Egger test did not include zero, a significant bias occurred in the publication of the results (coefficient=11.58;  $T=4.39$ ;  $P=0.001$ ; 95% CI, 6.23–16.93). The funnel plot is shown in Fig. 3.

The subgroup analysis by continent showed that the pooled prevalence of *Toxocara* in pediatric patients in Asia, America, Africa, and Europe was 35% (95% CI, 3%–67%;  $I^2=99.43\%$ ;  $P=0.00$ ), 31% (95% CI, 22%–40%;  $I^2=99.01\%$ ;  $P=0.00$ ), 21% (95% CI, 1%–52%;  $I^2=98.75\%$ ;  $P=0.00$ ), and 26% (95% CI, 19%–34%;  $I^2=85.94\%$ ;  $P=0.00$ ), respectively (Table 2 and Fig. 4).

### 1. Meta-regression analysis

We used a meta-regression analysis to assess the effect of suspected variables such as year of study and sample size on heterogeneity. The results of the meta-regression analysis shown in Table 2 did not show any significant association between this variable and the prevalence of *Toxocara* spp. in pediatric patients (Table 3 and Fig. 5).

**Table 1. Studies examining the prevalence of *Toxocara* spp. in pediatric patients**

Study	Country	Year	Sample size (n)	Age range (yr)	Specimen	Study design	Prevalence (%)	Methods	NOS score
Sadjjadi et al. <sup>21)</sup>	Iran	2000	519	6–13	Serum	CS	51.30	ELISA	6
Alonso et al. <sup>33)</sup>	Brazil	2000	206	1–14	Serum	CS	37.9	SLISA	7
Aguiar-Santos et al. <sup>34)</sup>	Brazil	2004	386	0–18	Serum	CS	39.4	ELISA	7
Muradian et al. <sup>35)</sup>	Brazil	2005	338	1–15	Serum	CS	79.40	ELISA	7
Paludo et al. <sup>36)</sup>	Brazil	2007	450	1–12	Serum	CS	28.8	ELISA	7
Nourian et al. <sup>37)</sup>	Iran	2008	810	1–2	Serum	CS	2.7	ELISA	6
Espinoza et al. <sup>38)</sup>	Peru	2008	182	6–12	Serum	CS	32.5	ELISA	6
Zarnowska et al. <sup>39)</sup>	Poland	2008	343	-	Serum	CS	24.70	ELISA	6
Dar et al. <sup>40)</sup>	India	2008	110	5–16	Serum	CS	32.7	ELISA	6
Antonios et al. <sup>41)</sup>	Egypt	2008	128	1–12	Serum	CS	6	ELISA	6
Alavi et al. <sup>42)</sup>	Iran	2008	29	6–15	Serum	CS	55	ELISA	7
Sviben et al. <sup>43)</sup>	Croatia	2009	142	3–18	Serum	CS	43	ELISA	7
Yazar et al. <sup>44)</sup>	Turkey	2010	112	-	Stool	CS	21.4	ELISA	6
Santar m et al. <sup>45)</sup>	Brazil	2011	252	1–15	Serum	CS	11.10	ELISA	6
Mattia et al. <sup>46)</sup>	Brazil	2012	353	0–12	Serum	CS	36.8	ELISA	8
Manini et al. <sup>9)</sup>	Brazil	2012	90	1–12	Serum	CS	17.80	ELISA	7
Sariego et al. <sup>47)</sup>	Cuban	2012	1,011	5–14	Serum	CS	38.80	ELISA	6
Schoenardie et al. <sup>48)</sup>	Brazil	2013	427	1–12	Serum	CS	50.60	ELISA	6
Kanobana et al. <sup>49)</sup>	Cuban	2013	958	5–14	Serum	CS	40	ELISA	6
Guilherme et al. <sup>50)</sup>	Brazil	2013	167	0–15	Serum	CS	4.2	ELISA	7
Pautova et al. <sup>51)</sup>	Russia	2013	144	1–17	Serum	CS	18.8	ELISA	8
Mendon a et al. <sup>52)</sup>	Brazil	2013	1,309	4–11	Serum	CS	48.4	ELISA	7
Oliart-Guzm n et al. <sup>53)</sup>	Brazil	2014	539	6 m–69 m	Serum	CS	23–28	ELISA	7
Archelli et al. <sup>54)</sup>	Spain	2014	120	0–3	Serum	CS	38.3	ELISA	7
Marchioro et al. <sup>55)</sup>	Brazil	2015	554	1–12	Serum	CS	7.4	ELISA	7
Mart nez et al. <sup>56)</sup>	Venezuela	2015	224	1–6	Serum	CS	29	ELISA	7
Cort s et al. <sup>57)</sup>	Mexico	2015	183	3–16	Serum	CS	12	ELISA	7
Mazur-Melewska et al. <sup>23)</sup>	Poland	2016	42	1–18	Serum	CS	30.3	ELISA	6
Gabrielli et al. <sup>57)</sup>	Serbia	2017	40	2–14	Serum	CS	10	ELISA/WB	7
Sowemimo et al. <sup>58)</sup>	Nigeria	2017	308	0–5	Serum	CS	37	WB	7
Fialho et al. <sup>59)</sup>	Brazil	2017	200	1–12	Serum	CS	16	ELISA	7

NOS, Newcastle–Ottawa scale; CS, cross-sectional; ELISA, enzyme-linked immunosorbent assay; CE, cryptogenic epilepsy; WB, Western blot.




Fig. 2. Meta-analysis of the global prevalence of *Toxocara* spp. in pediatric patients.




Fig. 3. Publication bias of the prevalence of *Toxocara* spp. in pediatric patients. CI, confidence interval.

## Discussion

*Toxocara* is a worldwide worm and common intestinal parasite for cats and dogs that have the ability to infect humans.<sup>14)</sup> *Toxocara* can be responsible for a variety of clinical manifestations.<sup>14)</sup> The worm's eggs can pass through the feces of animals and preserve infectivity for a long time in the soil.<sup>14)</sup> Soil contamination with *Toxoplasma* is more frequent in humans.<sup>15)</sup>

Table 2. Pooled prevalence of *Toxocara* spp. in pediatric patients by continent

Continents	Prevalence (95% CI)	Between studies			Between subgroups	
		$I^2$	Q	Pheterogeneity	Q	Pheterogeneity
Africa	21% (1–52)	98.75%	80.25	0.001		
American	31% (22–40)	98.83%	172.82	0.001	1.01	0.80
Asian	35% (11–58)	98.95%	523.25	0.081		
European	21% (1–52)	88.45%	42.67	0.001		

CI, confidence interval.

It can be concluded that in some cases, closer contact with animals can increase the exposure risk for this parasite.<sup>9,16)</sup> The current study aimed to systematically review the prevalence of *Toxocara* infection in pediatric patients. The results of 31 relevant studies indicated that the global prevalence of *Toxocara* in pediatric patients was 30 (95% CI, 22%–37%;  $I^2=99.11\%$ ;  $P=0.00$ ). The prevalence may vary among sample populations and geographical regions.

Oliart-Guzmán et al.<sup>17)</sup> investigated the seroprevalence of *Toxocara* in households with children in Western Brazilian Amazon over 7 years. They concluded that the prevalence of infection in pediatric patients less than 5 years of age was 28%, 23.3%, and 13.9% in 2003, 2010, and 2011, respectively. Oliart-Guzmán et al.<sup>17)</sup> suggested that water quality and the treatment of infected animals can be an appropriate strategy for preventing infection in these patients. Roldan et al.<sup>18)</sup> investigated eosinophilia and other risk factors of *Toxocara* infection. They used 2 groups of seropositive and seronegative pediatrics. Their results showed that a dry cough and eosinophilia are significantly associated with *Toxocara* infection.<sup>17)</sup>

Serologic techniques are reliable methods that can detect larval antiantigens. The most commonly used serologic test is ELISA testing, which applies the secretion antigens of the parasite larvae.<sup>2)</sup> Seroepidemiological evaluations in different countries have shown a global distribution of toxocarosis. The prevalence in American pediatrics is 4.6%–7.3% in the USA, 2.5% in Germany, and 19% in the Netherlands.<sup>19)</sup> In Iran, the prevalence among school children was 25.6% in Shiraz and 31% in Ilam.<sup>20,21)</sup> Musso et al.<sup>22)</sup> reported the association of viral and bacterial central nervous system infections in pediatrics with *Toxocara* by evaluating the serum and cerebrospinal fluid of 381 patients. *Toxocara* immunoglobulin G (IgG) was present in 32% of meningitis and 34% of control group patients, a difference that was not statistically significant.

As mentioned above, *Toxocara* can have a variety of clinical manifestations.<sup>14)</sup> Mazur-Melewska et al.<sup>23)</sup> evaluated the pulmonary presentation of *Toxocara* in 119 positive patients who were 1–19 years of age. Their results suggested that high levels of eosinophilia and hyperimmunoglobulinemia E could be related to *Toxocara* infection. In addition, Pinelli et al.<sup>24)</sup> assessed *Toxocara* infection in patients with suspected VLM and OLM from 1998 to 2009. Their results indicated a significantly




Fig. 4. Global prevalence (%) of *Toxocara* spp. in pediatric patients by continent.

Table 3. Meta-regression analysis to assess the effect of suspected variables on the pooled prevalence of *Toxocara* spp. in pediatric patients

Prevalence	Univariable model			Multivariable model		
	$\beta$	SE	<i>P</i> value (95% CI)	$\beta$	SE	<i>P</i> value (95% CI)
<i>Toxocara</i> spp. in the pediatrics						
Sample size	0.001	0.0003	0.388 (-0.001 to 0.003)	0.002	0.003	0.370 (-0.001 to 0.003)
Years of published	-0.013	0.008	0.084 (-0.001 to 0.003)	-0.014	0.008	0.094 (-0.300 to 0.002)

SE, standard error; CI, confidence interval.




Fig. 5. Meta-regression graph of the prevalence of *Toxocara* spp. in pediatric patients by sample size and publication year.

decreased rate of infection in the Netherlands that has increased over time as the children grew up.

Epilepsy is a neurological disorder that leads to epileptic seizures.<sup>25,26</sup> Epilepsy can be idiopathic or due to trauma, hypoxia, or infection.<sup>27,28</sup> El-Tantawy et al.<sup>29</sup> assessed *Toxocara* infection in cryptogenic epilepsy patients. The etiology was unknown in these patients, but brain diseases are mostly suspected. Anti-*Toxocara* IgG was found in 48% of the cryptogenic epilepsy patients and 46 of the controls, but the difference was not statistically significant.<sup>29,30</sup>

Sharghi et al.<sup>31</sup> investigated *Toxocara* infection as a risk factor for asthma in 95 patients aged 2–15 years and 229 controls. The result showed no statistically significant association between *Toxocara* and asthma, but *Toxocara* prevalence showed a

significantly higher rate in Hispanic children of Puerto Rican descent. It can be concluded that this race is more susceptible to the disease. In addition, Silva et al.<sup>32</sup> reported the prevalence of *Toxocara* as a risk factor for atopia and asthma. They reported that the prevalence in northern Brazil is 63% in 791 patients and there is an association between *Toxocara* infection and serum IgE causing cross-reaction and atopia.

These results show a 35% prevalence of *Toxocara* infection in Asian pediatrics, a rate that is higher than that in other continents. We assume that the factors responsible for this variation likely represent differences in public health and sanitation status, cultural and social conditions, environmental hygiene, and climate.<sup>31,32</sup> This was a comprehensive meta-analysis of 31 valid publications evaluating 10,676 pediatrics on this topic. Most of








the evaluated studies had an appropriate study population. The possibility that some patients were included in more than one report was low. The number of case reports in our assay was low, which leads to a lower risk of publication bias and increases the level of evidence of our findings. The limitations of this study are its high heterogeneity in the pooled estimate, differences in the diagnostic methods, and study population in primary studies.

According to this systematic review and meta-analysis, the global prevalence of *Toxocara* in pediatrics varies widely among geographical regions. The prevalence of *Toxocara* in Asian pediatrics was higher than those in other continents, which shows that in this country and in other continents, health policymakers should be more focused on future research and approaches related to *Toxocara* and other zoonotic diseases, improve the culture, and identify socioeconomically important factors.

## Footnotes

Conflicts of interest: No potential conflict of interest relevant to this article was reported.

### ORCID:

Behnam Abedi  <https://orcid.org/0000-0002-9016-8952>  
 Mehran Akbari  <https://orcid.org/0000-0002-1699-1051>  
 Sahar KkodaShenas  <https://orcid.org/0000-0002-1801-9119>  
 Alireza Tabibzadeh  <https://orcid.org/0000-0003-0070-2208>  
 Ali Abedi  <https://orcid.org/0000-0002-0019-1623>  
 Reza Ghasemikhah  <https://orcid.org/0000-0002-9677-7484>  
 Marzieh Soheili  <https://orcid.org/0000-0002-1170-2839>  
 Shnoo Bayazidi  <https://orcid.org/0000-0001-6167-3688>  
 Yousef Moradi  <https://orcid.org/0000-0002-2936-5930>

## References

- Macpherson CN. The epidemiology and public health importance of toxocarosis: a zoonosis of global importance. *Int J Parasitol* 2013;43:999-1008.
- Magnaval JF, Glickman LT, Dorchie P, Morassin B. Highlights of human toxocarosis. *Korean J Parasitol* 2001;39:1-11.
- Schacher JF. A contribution to the life history and larval morphology of *Toxocara canis*. *J Parasitol* 1957;43:599-610 passim.
- Degouy A, Menat C, Aubin F, Piarroux R, Woronoff-Lemsi MC, Humbert P. La toxocarose Toxocarosis. *Presse Med* 2001;30(39-40 Pt 1):1933-8.
- Sharma R, Singh BB, Gill JP. Larva migrans in India: veterinary and public health perspectives. *J Parasit Dis* 2015;39:604-12.
- Buijs J, Borsboom G, van Gemund JJ, Hazebroek A, van Dongen PA, van Knapen F, et al. Toxocara seroprevalence in 5-year-old elementary schoolchildren: relation with allergic asthma. *Am J Epidemiol* 1994;140:839-47.
- Genchi C, Di Sacco B, Gatti S, Sangalli G, Scaglia M. Epidemiology of human toxocarosis in northern Italy. *Parassitologia* 1990;32:313-9.
- MacLean JD, Graeme-Cook FM. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 12-2002. A 50-year-old man with eosinophilia and fluctuating hepatic lesions. *N Engl J Med* 2002;346:1232-9.
- Manini MP, Marchioro AA, Colli CM, Nishi L, Falavigna-Guilherme AL. Association between contamination of public squares and seropositivity for *Toxocara* spp. in children. *Vet Parasitol* 2012;188:48-52.
- Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *PLoS Med* 2007;4:e297.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007;147:573-7.
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
- Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute, 2011.
- Thullier P, Guglielmo V, Rajerison M, Chanteau S. Short report: Serodiagnosis of plague in humans and rats using a rapid test. *Am J Trop Med Hyg* 2003;69:450-1.
- Won KY, Kruszon-Moran D, Schantz PM, Jones JL. National seroprevalence and risk factors for Zoonotic *Toxocara* spp. infection. *Am J Trop Med Hyg* 2008;79:552-7.
- Gennari SM, Kasai N, de Jesus Pena HF, Cortez A. Ocorrência de protozoários e helmintos em amostras de fezes de cães e gatos da cidade de São Paulo. *Braz J Vet Res Anim Sci* 1999;36:87-91.
- Oliart-Guzmán H, Delfino BM, Martins AC, Mantovani SA, Braña AM, Pereira TM, et al. Epidemiology and control of child toxocarosis in the western Brazilian Amazon - a population-based study. *Am J Trop Med Hyg* 2014;90:670-81.
- Roldán WH, Espinoza YA, Atúnar A, Ortega E, Martínez A, Saravia M. Frequency of eosinophilia and risk factors and their association with *Toxocara* infection in schoolchildren during a health survey in the north of Lima, Peru. *Rev Inst Med Trop Sao Paulo* 2008;50:273-8.
- Overgaauw PA. Aspects of *Toxocara* epidemiology: human toxocarosis. *Crit Rev Microbiol* 1997;23:215-31.
- Sadjjadi SM, Khosravi M, Mehrabani D, Orya A. Seroprevalence of toxocara infection in school children in Shiraz, southern Iran. *J Trop Pediatr* 2000;46:327-30.
- Shokouhi S, Abdi J. Seroprevalence of *Toxocara* in children from urban and rural areas of Ilam Province, West Iran. *Osong Public Health Res Perspect* 2018;9:101-4.
- Musso C, Lemos EM, Tsanaclis AM, Pereira FE. *Toxocara* infection is not associated with viral or bacterial central nervous system infection in children. *Neuropediatrics* 2006;37:126-9.
- Mazur-Melewska K, Jończyk-Potoczna K, Kemnitz P, Mania A, Figlerowicz M, Służewski W. Pulmonary presentation of *Toxocara* sp. infection in children. *Pneumonol Alergol Pol* 2015;83:250-5.
- Pinelli E, Herremans T, Harms MG, Hoek D, Kortbeek LM. *Toxocara* and *Ascaris* seropositivity among patients suspected of visceral and ocular larva migrans in the Netherlands: trends from 1998 to 2009. *Eur J Clin Microbiol Infect Dis* 2011;30:873-9.
- Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. *Epilepsia* 2014;55:475-82.
- Chang BS, Lowenstein DH. Epilepsy. *N Engl J Med* 2003;349:1257-66.
- Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). *Epilepsia* 2005;46:470-2.
- Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. *Epilepsia* 1975;16:1-66.
- El-Tantawy NL, El-Nahas HA, Salem DAB, Salem NAB, Hasaneen BM. Seroprevalence of *Toxoplasma gondii* and *Toxocara* spp. in children with cryptogenic epilepsy. *Am J Infect Dis Microbiol* 2013;1:92-5.
- Rostami A, Sepidarkish M, Ma G, Wang T, Ebrahimi M, Fakhri Y,

- et al. Global prevalence of *Toxocara* infection in cats. *Adv Parasitol* 2020;109:615-39.
31. Sharghi N, Schantz PM, Caramico L, Ballas K, Teague BA, Hotez PJ. Environmental exposure to *Toxocara* as a possible risk factor for asthma: a clinic-based case-control study. *Clin Infect Dis* 2001;32:E111-6.
  32. Silva MB, Amor ALM, Santos LN, Galvão AA, Oviedo Vera AV, Silva ES, et al. Risk factors for *Toxocara* spp. seroprevalence and its association with atopy and asthma phenotypes in school-age children in a small town and semi-rural areas of Northeast Brazil. *Acta Trop* 2017;174:158-64.
  33. Alonso JM, Bojanich MV, Chamorro M, Gorodner JO. *Toxocara* seroprevalence in children from a subtropical city in Argentina. *Rev Inst Med Trop Sao Paulo* 2000;42:235-7.
  34. Aguiar-Santos AM, Andrade LD, Medeiros Z, Chieffi PP, Lescano SZ, Perez EP. Human toxocariasis: frequency of anti-*Toxocara* antibodies in children and adolescents from an outpatient clinic for lymphatic filariasis in Recife, Northeast Brazil. *Rev Inst Med Trop Sao Paulo* 2004;46:81-5.
  35. Muradian V, Gennari SM, Glickman LT, Pinheiro SR. Epidemiological aspects of Visceral Larva Migrants in children living at São Remo Community, São Paulo (SP), Brazil. *Vet Parasitol* 2005;134:93-7.
  36. Paludo ML, Falavigna DL, Elefant GR, Gomes ML, Baggio ML, Amadei LB, et al. Frequency of *Toxocara* infection in children attended by the health public service of Maringá, south Brazil. *Rev Inst Med Trop Sao Paulo* 2007;49:343-8.
  37. Nourian AA, Amiri M, Ataiean A, Haniloo A, Mosavinasab SN, Badali H. Seroepidemiological study for toxocariasis among children in Zanjan-northwest of Iran. *Pak J Biol Sci* 2008;11:1844-7.
  38. Espinoza YA, Huapaya PH, Roldán WH, Jiménez S, Arce Z, Lopez E. Clinical and serological evidence of *Toxocara* infection in school children from Morrope district, Lambayeque, Peru. *Rev Inst Med Trop Sao Paulo* 2008;50:101-5.
  39. Zarnowska H, Borecka A, Gawor J, Marczyńska M, Dobosz S, Basiak W. A serological and epidemiological evaluation of risk factors for toxocariasis in children in central Poland. *J Helminthol* 2008;82:123-7.
  40. Dar ZA, Tanveer S, Yattoo GN, Sofi BA, Dar PA, Wani SA. Presence of anti-*Toxocara* antibodies in children population of district Anantnag and Pulwama of Kashmir valley. *Indian J Med Microbiol* 2008;26:400-2.
  41. Antonios SN, Eid MM, Khalifa EA, Othman AA. Seroprevalence study of *Toxocara canis* in selected Egyptian patients. *J Egypt Soc Parasitol* 2008;38:313-8.
  42. Alavi SM, Sefidgaran G. Frequency of anti *Toxocara* antibodies in schoolchildren with chronic cough and eosinophilia in Ahwaz, Iran, 2006. *Pak J Med Sci* 2008;24:360-3.
  43. Sviben M, Cavlek TV, Missoni EM, Galinović GM. Seroprevalence of *Toxocara canis* infection among asymptomatic children with eosinophilia in Croatia. *J Helminthol* 2009;83:369-71.
  44. Yazar S, Yaman O, Cetinkaya U, Hamamci B, Sahin I. Investigation of anti-*Toxocara canis* IgG antibodies in patients presenting at The Erciyes University Medical Faculty, Department of Parasitology. *Turkiye Parazitoloj Derg* 2010;34:24-6.
  45. Santarém VA, Leli FN, Rubinsky-Elefant G, Giuffrida R. Protective and risk factors for toxocariasis in children from two different social classes of Brazil. *Rev Inst Med Trop Sao Paulo* 2011;53:66-72.
  46. Mattia S, Colli CM, Adami CM, Guilherme GF, Nishi L, Rubinsky-Elefant G, et al. Seroprevalence of *Toxocara* infection in children and environmental contamination of urban areas in Paraná State, Brazil. *J Helminthol* 2012;86:440-5.
  47. Sariego I, Kanobana K, Junco R, Vereecken K, Núñez FA, Polman K, et al. Frequency of antibodies to *Toxocara* in Cuban schoolchildren. *Trop Med Int Health* 2012;17:711-4.
  48. Schoenardie ER, Scaini CJ, Brod CS, Pepe MS, Villela MM, McBride AJ, et al. Seroprevalence of *Toxocara* infection in children from southern Brazil. *J Parasitol* 2013;99:537-9.
  49. Kanobana K, Vereecken K, Junco Diaz R, Sariego I, Rojas L, Bonet Gorbea M, et al. *Toxocara* seropositivity, atopy and asthma: a study in Cuban schoolchildren. *Trop Med Int Health* 2013;18:403-6.
  50. Guilherme EV, Marchioro AA, Araujo SM, Falavigna DL, Adami C, Falavigna-Guilherme G, et al. Toxocariasis in children attending a Public Health Service Pneumology Unit in Paraná State, Brazil. *Rev Inst Med Trop Sao Paulo* 2013;55:S0036-46652013000300189.
  51. Pautova EA, Dovgalev AS, Astanina S. Toxocariasis in children and adolescents with allergic and bronchopulmonary diseases, HIV infection, hepatitis B and C risk groups: results of serological screening. *Med Parazitol (Mosk)* 2013;(2):13-7.
  52. Mendonça LR, Figueiredo CA, Esquivel R, Fiaccone RL, Pontes-de-Carvalho L, Cooper P, et al. Seroprevalence and risk factors for *Toxocara* infection in children from an urban large setting in Northeast Brazil. *Acta Trop* 2013;128:90-5.
  53. Archelli S, Santillan GI, Fonrouge R, Céspedes G, Burgos L, Radman N. Toxocariasis: seroprevalence in abandoned-institutionalized children and infants. *Rev Argent Microbiol* 2014;46:3-6.
  54. Marchioro AA, Colli CM, Ferreira EC, Viol BM, Araújo SM, Falavigna-Guilherme AL. Risk factors associated with toxoplasmosis and toxocariasis in populations of children from nine cities in southern Brazil. *J Helminthol* 2015;89:428-32.
  55. Martínez M, García H, Figuera L, González V, Lamas F, López K, et al. Seroprevalence and risk factors of toxocariasis in preschool children in Aragua state, Venezuela. *Trans R Soc Trop Med Hyg* 2015;109:579-88.
  56. Cortés NN, Núñez CR, Guiliana BG, García PA, Cárdenas RH. Presence of anti-*Toxocara canis* antibodies and risk factors in children from the Amecameca and Chalco regions of México. *BMC Pediatr* 2015;15:65.
  57. Gabrielli S, Tasić-Otašević S, Ignjatović A, Fraulo M, Trenkić-Božinović M, Momčilović S, et al. Seroprevalence and risk factors for *Toxocara canis* infection in Serbia during 2015. *Foodborne Pathog Dis* 2017;14:43-9.
  58. Sowemimo OA, Lee YL, Asaolu SO, Chuang TW, Akinwale O, Badejoko BO, et al. Seroepidemiological study and associated risk factors of *Toxocara canis* infection among preschool children in Osun State, Nigeria. *Acta Trop* 2017;173:85-9.
  59. Fialho PMM, Correa CRS, Lescano SZ. Asthma and Seroconversion from *Toxocara* spp. infection: which comes first? *Biomed Res Int* 2018; 2018:4280792.

**How to cite this article:** Abedi B, Akbari M, KkodaShenas S, Tabibzadeh A, Abedi A, Ghasemikhah R, et al. The global prevalence of *Toxocara* spp. in pediatrics: a systematic review and meta-analysis. *Clin Exp Pediatr* 2021;64:575-81. <https://doi.org/10.3345/cep.2020.01039>